HomeFinTechStarpharma: Receives $7.7m R&D tax refund

Starpharma: Receives $7.7m R&D tax refund

Date:

Flex Expands Consumer Reach with Strategic Maza Acquisition

Flex's $40M acquisition of Maza aims to revolutionize financial...

Flex Expands Consumer Reach Through Strategic Maza Acquisition

Unlocking New Opportunities in Consumer Markets with Innovative Solutions Highlights:...

Mongolian Fintech LendMN Secures $20 Million to Enhance Financial Inclusion

Revolutionizing Access to Financial Services in Mongolia Highlights: LendMN raises...

Starpharma Receives $7.7m R&D tax refund

  • Starpharma (SPL) receives a $7.7 million research and development tax incentive refund
  • The refund falls under the Australian Federal Government’s R&D Tax Incentive Scheme
  • The funds were granted in relation to the company’s activities during the 2021 financial year, including development of its DEP oncology products and VIRALEZE antiviral nasal spray
  • This follows $1 million in funding awarded to the company for the development of VIRALEZE provided through the Australian Government’s Medical Future Fund Biomedical Translation Bridge program
  • The company dips 1.72 per cent, trading at $1.14 at 2:40pm AEDT
Exit mobile version